These results suggest that ARHGEF9 and SLPI are promising diagnostic biomarkers for AP and T2DM, which may facilitate early diagnosis and prompt treatment in clinical settings. This evidence concerns the gene ARHGEF9 and type 2 diabetes mellitus.